1-[(5-Azido-2-nitrophenyl)methoxy]pyrrolidine-2,5-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(5-Azido-2-nitrophenyl)methoxy]pyrrolidine-2,5-dione
• 化学式: C11H9N5O5
• 分子量: 291.22
• InChiKey: KWBGHMPXFVRHOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  107
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• Immobilisation and stabilisation of virus
  申请人：University of Strathclyde

  公开号：EP1982723A1

  公开（公告）日：2008-10-22

  The present invention relates to a method for immobilization and optional stabilization of viruses whilst retaining the viral biological activity and the use of immobilized virus in therapy. In particular, the immobilized virus relates to immobilized bacteriophage and their use as an antibiotic or bacteriostatic agent and in the treatment of antibiotic-resistant infections.

  本发明涉及一种在保持病毒生物活性的同时固定和可选稳定病毒的方法，以及将固定病毒用于治疗的方法。 特别是，固定化病毒涉及固定化噬菌体及其作为抗生素或抑菌剂和治疗抗生素耐药性感染的用途。
• Complement factor H-derived short consensus repeat-antibody constructs
  申请人：Medizinische Universität Innsbruck

  公开号：EP2208737A1

  公开（公告）日：2010-07-21

  The present invention relates to a complement activating construct comprising a complement factor H-derived short consensus repeat (fH-derived SCR) and a binding molecule which specifically recognizes a pathogen. More specifically, the fH-derived SCR is selected from the group consisting of SCR7, SCR9, SCR13, SCR18-20 and artificial SCR (aSCR). Furthermore, an in vivo method for screening complement-based approaches for the treatment of the prevention, treatment or amelioration of an infection with a pathogen or a pathological condition associated with an infection with a pathogen is described.

  本发明涉及一种补体激活构建物，该构建物由补体因子 H 衍生的短共识重复序列（fH-derived SCR）和特异性识别病原体的结合分子组成。更具体地说，fH-衍生SCR选自SCR7、SCR9、SCR13、SCR18-20和人工SCR（aSCR）组成的组。此外，还描述了一种体内方法，用于筛选基于补体的治疗方法，以预防、治疗或改善病原体感染或与病原体感染相关的病理状况。
• XTEN conjugate compositions and methods of making same
  申请人：Amunix Operating Inc.

  公开号：US10172953B2

  公开（公告）日：2019-01-08

  The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.

  本发明涉及扩展重组多肽（XTEN）组合物、包含XTEN和与交联剂连接的XTEN的共轭组合物、用于与药理活性载荷共轭的交联剂、制造高纯度XTEN的方法、制造XTEN-交联剂和XTEN-载荷共轭物的方法以及使用XTEN-交联剂和XTEN-载荷组合物的方法。
• Tubular nanostructure targeted to cell membrane
  申请人：Deep Science, LLC

  公开号：US10683365B2

  公开（公告）日：2020-06-16

  Devices, compositions, and methods are described which provide a tubular nanostructure or a composite tubular nanostructure targeted to a lipid bilayer membrane. The tubular nanostructure includes a hydrophobic surface region flanked by two hydrophilic surface regions. The tubular nanostructure is configured to interact with a lipid bilayer membrane and form a pore in the lipid bilayer membrane. The tubular nanostructure may be targeted by including at least one ligand configured to bind to one or more cognates on the lipid bilayer membrane of a target cell.

  本文描述了针对脂质双层膜的管状纳米结构或复合管状纳米结构的装置、组合物和方法。管状纳米结构包括一个疏水表面区域和两个亲水表面区域。管状纳米结构可与脂质双层膜相互作用，并在脂质双层膜上形成孔隙。管状纳米结构可通过包含至少一种配体来靶向，这种配体可与靶细胞脂质双层膜上的一种或多种同源物结合。
• Affinity medicant conjugate
  申请人：AF Chemicals, LLC

  公开号：US10806708B2

  公开（公告）日：2020-10-20

  In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.

  在本发明的一个实施方案中，一种用于治疗细胞群的组合物包含一种亲和药剂共轭物（AMC）。药剂分子可以是包括酰化芬在内的毒素或药物分子。亲和剂可以是抗体、结合蛋白、类固醇、脂质、生长因子、蛋白质、肽或非肽。亲和分子可以通过连接体与药物共价结合。新型连接体可根据溶液 pH 值定向连接半胱氨酸、精氨酸或赖氨酸残基，从而更灵活地保留和/或生成 AMC 中的特定表位。